VEXAS综合征与慢性粒单核细胞白血病相关结节性多动脉炎:病例对照研究
该多中心回顾性病例对照研究纳入12例VEXAS相关PAN、11例CMML相关PAN,并按年龄性别与原发性PAN匹配,发现继发性PAN发病年龄更晚,VEXAS-PAN皮肤、睾丸和眼部表现更突出,且缓解率更低、复发率更高、死亡率更高。
要点
- VEXAS-PAN发病年龄73岁、CMML-PAN为70岁,均高于原发性PAN的54岁(P<0.01)。
- VEXAS-PAN皮肤表现100%、睾丸炎67%、眼部表现58%,均高于原发性PAN。
- VEXAS-PAN缓解率更低(aOR 0.15;95%CI 0.02-1.00)、复发风险更高(aHR 3.24;P=0.043)。
核心结论
- VEXAS相关PAN与CMML相关PAN是不同于原发性PAN的独立临床实体,预后更差且治疗挑战独特。
- 早期识别并个体化管理对改善这类患者结局至关重要。
研究设计与样本
- 多中心回顾性病例对照研究,纳入23例患者(12例VEXAS-PAN、11例CMML-PAN)。
- 每例VEXAS-PAN或CMML-PAN按年龄和性别匹配3例原发性PAN。
- 分析基线特征、治疗特征、生存率与复发率。
主要发现
- 继发性PAN发病年龄更晚:VEXAS-PAN为73岁、CMML-PAN为70岁,原发性PAN为54岁(P<0.01)。
- VEXAS-PAN皮肤表现100%、睾丸炎67%、眼部表现58%,均高于原发性PAN。
- CMML-PAN临床特征与原发性PAN高度相似。
- VEXAS-PAN缓解率低于原发性PAN(aOR 0.15;95%CI 0.02-1.00),复发风险更高(aHR 3.24;P=0.043)。
- CMML-PAN缓解率(aOR 0.12;95%CI 0.02-0.73)与复发风险(aHR 2.23;P=0.145)呈相似趋势。
关键数值与推荐
- VEXAS-PAN与原发性PAN比较:缓解aOR 0.15(95%CI 0.02-1.00),复发aHR 3.24(P=0.043)。
- CMML-PAN与原发性PAN比较:缓解aOR 0.12(95%CI 0.02-0.73),复发aHR 2.23(P=0.145)。
- 发病年龄:VEXAS-PAN 73岁、CMML-PAN 70岁、原发性PAN 54岁(P<0.01)。
- 死亡率:VEXAS-PAN 50%、CMML-PAN 15%、原发性PAN 17%。
临床怎么用
- 对年龄偏大、伴皮肤、睾丸或眼部表现的PAN患者,应警惕VEXAS或CMML相关可能。
- 继发性PAN缓解率低、复发风险高,需个体化治疗与密切随访。
- VEXAS-PAN死亡率高,早期识别和针对性管理可能改善预后。
局限性
- 回顾性、多中心设计,样本量小(共23例)。
- 原文摘要未报告匹配后原发性PAN的具体例数及更详细的偏倚控制方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Polyarteritis nodosa (PAN) is a rare necrotizing vasculitis occurring alone or associated with other conditions, including VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome and chronic myelomonocytic leukaemia (CMML). We aimed to compare the presentation and outcomes of VEXAS- or CMML-associated PAN (VEXAS-PAN and CMML-PAN) with those of primary PAN. METHODS: We conducted a retrospective, multicentre study of patients diagnosed with primary PAN, VEXAS-PAN or CMML-PAN. Each VEXAS-PAN or CMML-PAN case was matched to three primary PAN cases by age and gender. We analysed baseline and therapeutic characteristics, along with survival and relapse rates. RESULTS: Twenty-three patients were included (12 with VEXAS-PAN, 11 with CMML-PAN). Secondary PAN occurred at older ages: 73 years for VEXAS-PAN, 70 years for CMML-PAN and 54 years for primary PAN (P < 0.01). VEXAS-PAN was associated with a higher frequency of skin manifestations (100%), orchitis (67%) and ocular manifestations (58%) than primary PAN. By contrast, the clinical features of CMML-PAN closely resembled those of primary PAN. VEXAS-PAN was less likely than primary PAN to achieve remission [adjusted odds ratio (aOR) 0.15; 95% CI 0.02-1.00] and more likely to experience relapses [adjusted hazard ratio (aHR) 3.24; P = 0.043]. Similar trends were observed for CMML-PAN regarding remission (aOR 0.12; 95% CI 0.02-0.73) and relapses (aHR 2.23; P = 0.145). Mortality was higher in VEXAS-PAN (50%) than in CMML-PAN (15%) or primary PAN (17%). CONCLUSION: VEXAS- and CMML-PAN are distinct clinical entities with poorer prognosis and unique therapeutic challenges. Recognizing these conditions early and providing individualized management are crucial to improving outcomes in these patients.
引用
- Cioni P, Nguyen Y, Rohmer J, et al. Polyarteritis nodosa associated with VEXAS syndrome and chronic myelomonocytic leukemia: a case-control study. Rheumatology (Oxford). 2026. PMID: 41437650. doi:10.1093/rheumatology/keaf685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。